See also Editorial by Franchini
C. J. N. Verkleij (1), D. J. F. Stuijver (2, 3), B. van Zaane (2, 3), A. Squizzato (4), D. P. M. Brandjes (2, 3), H. R. Büller (2), J. C. M. Meijers (1, 2), V. E. A. Gerdes (2, 3)
(1) Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; (2) Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; (3) Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands; (4) Department of Clinical Medicine, University of Insubria, Varese, Italy
Endocrine disorders affect both the coagulation and fibrinolytic systems, and have been associated with the development of cardiovascular diseases. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a link between coagulation and the fibrinolytic system. The aim of this study was to determine the effect of thyroid hormone excess and deficiency on TAFI levels and function. The effect of hyperthyroxinemia on TAFI was studied in healthy volunteers who were randomised to receive levothyroxine or no medication for 14 days in a crossover design. The effect of hypothyroidism on TAFI was studied in a multicentre observational cohort study. Blood was drawn before treatment of patients with newly diagnosed hypothyroidism and when euthyroidism was achieved. Plasma clot-lysis times, activated TAFI (TAFIa)-dependent prolongation of clot-lysis and TAFI levels were measured. Thyroid hormone excess resulted in a hypofibrinolytic condition and in an enhanced TAFIa-dependent prolongation of clot lysis. A trend towards decreased plasma TAFI levels was observed in healthy volunteers who used levothyroxine. Hypothyroidism resulted in hyperfibrinolysis and a reduced TAFIa-dependent prolongation of clot lysis. In conclusion, alterations of TAFIa-dependent prolongation of clot lysis in patients with thyroid disorders may cause an impaired haemostatic balance. The disturbed haemostatic balance in patients with hyperthyroidism might make them prone to thrombosis, while the risk for bleeding may increase in patients with hypothyroidism.
thyroid, fibrinolysis, coagulation, TAFI
Hämostaseologie 2007 27 4: 278-281
Marie-Christine Alessi, Irène Juhan-Vague
Thromb Haemost 2008 99 6: 995-1000
Fabrizio Semeraro*, Donatella Piro*, Maria R. Rossiello, Tiziana Ammollo, Mario Colucci
Thromb Haemost 2007 98 6: 1208-1214
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...